Publications by authors named "Ekaterina Guzev"
Finding synergistic drug combinations is an important area of cancer research. Here, we sought to rationally design synergistic drug combinations with an inhibitor of BTK kinase, ibrutinib, which is used for the treatment of several types of leukemia. We (a) used a pooled shRNA screen to identify genes that protect cells from the drug, (b) identified protective pathways via bioinformatics analysis of these gene sets, and (c) identified drugs that inhibit these pathways.
View Article and Find Full Text PDFArticle Synopsis
- Mathematical models are increasingly used in cancer research, particularly for Chronic Lymphocytic Leukemia (CLL), a common but incurable adult leukemia.
- The study focused on the growth of A20 leukemic cells in mice and tested the effectiveness of Ibrutinib and Cytarabine, resulting in a calculated killing rate for the cancer cells based on the treatments.
- The developed ordinary differential equations (ODEs) model effectively simulated drug efficacy, predicting a 95% kill rate of A20 cells when using the combination of both drugs, suggesting potential for personalized chemotherapy software.